Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan (Evomela/Maiveining) 200 mg/m² Conditioning Before Autologous HSCT in Multiple Myeloma – China Phase IV
CTR20200252Phase 4Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of melphalan in multiple myeloma (MM), sponsored by Spectrum Pharmaceuticals, Inc.. Started Mar 2020; status: completed.
02
Drugs
melphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20200252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200252.